Evidence map›Paper›PMID 18392786›Full record

ArticleEndocrine2008

Angiotensin II- and glucose-stimulated extracellular matrix production: mediation by the insulin-like growth factor (IGF) axis in a murine mesangial cell line.

Lori K Davis, Buel D Rodgers, Kevin M Kelley

Open access · greenAbstract read
In one paragraph

Article in Endocrine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Lori K DavisEndocrinology Laboratory, Department of Biological Sciences, California State University, Long Beach, Long Beach, CA, 90840, USA.
Buel D Rodgers
Kevin M Kelley
California State University, Long Beach · USWashington State University · US

Funding

Nuclear Actions of IGFBP-3 in Developing Muscle CellsR03AR051917 · NIAMS · WASHINGTON STATE UNIVERSITY · PI RODGERS, BUEL DANTESE · 2007 to 2009
$220k
Howard Hughes Medical Institute 52002663NIAMS NIH HHS R03 AR051917
6 · The paper itself

Abstract

In diabetic nephropathy, glomerular mesangial cells exhibit aberrant anabolic activity that includes excessive production of extracellular matrix (ECM) proteins, leading to crowding of filtration surface areas and possible renal failure. In the present study, a murine mesangial cell line (MES-13 cells) was studied to determine the roles of the renin-angiotensin system (RAS) and the insulin-like growth factor (IGF) axis in the anabolic response to elevated glucose levels. Culture of MES-13 cells in medium containing supra-physiological glucose concentrations (>5.5 mmol/l) resulted in increased production of ECM proteins including laminin, fibronectin, and heparan sulfate proteoglycan with concurrent increases in IGF-binding protein (IGFBP)-2 production. These responses were blocked by the angiotensin receptor antagonists saralasin and losartan, while exogenous angiotensin II (Ang II) treatment directly stimulated increases in ECM and IGFBP-2. In all experiments, IGFBP-2 levels were correlated with anabolic activity implicating IGFBP-2 as a possible mediator in cellular responses to high glucose and Ang II. Such mediation appears to involve IGFBP-2 modulation of IGF-I signaling, since all responses to high glucose or Ang II were blocked by immuno-neutralization of IGF-I. These data suggest alterations in the IGF axis as key mechanisms underlying nephropathic responses of mesangial cells to Ang II and high glucose.

Indexed as

Angiotensin IIAngiotensin II Type 1 Receptor BlockersAnimalsAntibodiesCell LineDose-Response Relationship, DrugExtracellular MatrixGlucoseInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor ILosartanMesangial CellsMiceReceptor, Angiotensin, Type 1Signal TransductionAngiotensin IIAngiotensin II Type 1 Receptor BlockersAntibodiesGlucoseInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor ILosartanReceptor, Angiotensin, Type 1

Identifiers

PMID18392786
PMCPMC2684556
OpenAlexW2034112797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.